Search Results
Fact Sheet
Genomic research has been central to understanding and combating the SARS-CoV-2 (COVID-19) pandemic.
… RNA to double-stranded DNA in a process called reverse transcription. The two DNA template strands are then …
Staff
Dr. Paul Liu is a senior investigator in NHGRI's Translational and Functional Genomics Branch.
​
… that form a dimer for DNA binding and gene expression regulation, are frequent targets of such chromosome … Sood, has used zebrafish to study the roles of several transcription factor genes in hematopoiesis, such as runx1 , … Freedman M, Siciliano MJ, and Collins FS. Fusion between transcription factor CBFb/PEBP2b and a myosin heavy chain in …
Policy Issues
Scientists have edited genomes for many years, but CRISPR technology has improved the speed, cost, accuracy, and efficiency of genome editing
​
… ZFN must be engineered for each new target DNA sequence. Transcription activator-like effector nucleases (TALENs) In 2009, a new class of proteins called Transcription Activator-Like Effector Nucleases (TALENs) …  arrived to the genome editing scene. Similar to ZFNs, transcription activator-like effector nucleases (TALENs) are …
Research at NHGRI
The Genetic Disease Research Branch studies how genetic changes affect the structure and function of gene products leading to human disease.
… in understanding how disruptions in signaling pathways and transcription factors contribute to disease. Our …
News Release
NIH awards more than $64 million to for a database of human cellular responses called the Library of Integrated Network-based Cellular Signatures or LINCS.
… year used LINCS data to identify the role of a critical transcription regulator, heat shock factor 1 (HSF1), in …
Educational Resources
An intron is a portion of a gene that does not code for amino acids.
… not remain in the final mature mRNA molecule following transcription of that gene and does not code for amino acids …
Research at NHGRI
The Metabolic Medicine Branch houses clinical and laboratory research programs that focus on the development of new therapies for patients with genetic disorders.
FAQ
Frequently asked questions related to the Informational Session on the Renewed ELSI Funding Opportunities: R01 (PAR-23-293), R21 (PAR-23-294), and R03 (PAR-23-295).